DRR168550
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.350
- ANDROGEN_RESPONSE+0.340
- OXIDATIVE_PHOSPHORYLATION+0.300
- WNT_BETA_CATENIN_SIGNALING+0.260
- APICAL_SURFACE+0.210
- PEROXISOME+0.190
- MYC_TARGETS_V1+0.170
- NOTCH_SIGNALING+0.150
- FATTY_ACID_METABOLISM+0.140
- ADIPOGENESIS+0.100
Top 10 suppressed
- E2F_TARGETS-0.430
- G2M_CHECKPOINT-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
- IL6_JAK_STAT3_SIGNALING-0.300
- MYOGENESIS-0.300
- INTERFERON_GAMMA_RESPONSE-0.260
- UV_RESPONSE_UP-0.260
- MTORC1_SIGNALING-0.250
- ANGIOGENESIS-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168534 | — | — | 0.859 |
| 2 | TCGA-E2-A1IU-01A-11R-A14D-07 | — | B | 0.800 |
| 3 | SRR650196 | — | — | 0.795 |
| 4 | TCGA-D8-A27V-01A-12R-A17B-07 | — | A | 0.772 |
| 5 | R370 | — | — | 0.765 |
| 6 | C3L-01889 | — | cohortA2 | 0.743 |
| 7 | TCGA-A7-A0CH-01A-21R-A00Z-07 | — | B | 0.737 |
| 8 | C3L-02961 | — | cohortA2 | 0.725 |
| 9 | MDT-AP-3303 | Med | Medulloblastoma | 0.724 |
| 10 | SRR8943006 | — | — | 0.720 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |